Back to top
more

Humana (HUM)

(Real Time Quote from BATS)

$264.86 USD

264.86
511,134

+8.72 (3.40%)

Updated Aug 8, 2025 03:04 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 5% (231 out of 244)

Industry: Medical - HMOs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Srijita Guha headshot

3 HMO 2019 Outperformers Likely to Retain Beat Streak in 2020

by Srijita Guha

HMO players are poised for growth on the back of higher revenues, membership growth, technological advancements and a solid capital position.

Sanghamitra Saha headshot

Trump Budget 2021 Likely to Impact These Sector ETFs

by Sanghamitra Saha

President Donald Trump delivered his latest budget proposal for 2021 and out these ETFs in focus.

Zacks Equity Research

Cigna (CI) Q4 Earnings and Revenues Beat Estimates, Rise Y/Y

by Zacks Equity Research

Cigna (CI) Q4 results reflect revenue and membership growth on the back of Express Scripts acquisition.

Zacks Equity Research

Company News for Feb 6, 2020

by Zacks Equity Research

Companies In The News Are: COTY, CPRI, HUM, GILD.

Zacks Equity Research

Humana (HUM) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Humana (HUM) delivered earnings and revenue surprises of 3.64% and 0.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cigna (CI) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Cigna's (CI) earnings performance is likely to have gained from the accretive Express Scripts acquisition.

Zacks Equity Research

Is a Surprise Coming for Humana (HUM) This Earnings Season?

by Zacks Equity Research

Humana (HUM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Amazon.com, Procter & Gamble, Pfizer, Southwest Airlines and Humana

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Amazon.com, Procter & Gamble, Pfizer, Southwest Airlines and Humana

Zacks Equity Research

Is a Beat in the Cards for Humana's (HUM) Earnings in Q4?

by Zacks Equity Research

Humana's (HUM) fourth-quarter results are likely to reflect lower membership, partly offset by higher revenues.

Sheraz Mian headshot

Q4 Earnings Scorecard and Analyst Reports for Amazon, Pfizer & Others

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), The Procter & Gamble Company (PG) and Pfizer Inc. (PFE).

Zacks Equity Research

Analysts Estimate Humana (HUM) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Humana (HUM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

What's in Store for HCA Healthcare's (HCA) Q4 Earnings?

by Zacks Equity Research

HCA Healthcare's (HCA) Q4 results are likely to reflect healthy growth in revenues and admissions.

Zacks Equity Research

Should Value Investors Pick Humana (HUM) Stock Right Now?

by Zacks Equity Research

Is Humana (HUM) a great pick from the value investor's perspective right now? Read on to know more.

Zacks Equity Research

Why Should You Retain MEDNAX (MD) Stock in Your Portfolio?

by Zacks Equity Research

Riding high on its rising revenue stream and inorganic growth profile, MEDNAX (MD) holds potential to benefit its investors.

Zacks Equity Research

Zacks.com featured highlights include: Calavo Growers, BMC Stock, Humana, Vipshop and AllianceBernstein

by Zacks Equity Research

Zacks.com featured highlights include: Calavo Growers, BMC Stock, Humana, Vipshop and AllianceBernstein

Sanghamitra Saha headshot

5 Top-Ranked DuPont-Confirmed Quality Stocks

by Sanghamitra Saha

DuPont technique examines operating management, management of assets and capital structure to find out the financial condition of a company.

Zacks Equity Research

UnitedHealth (UNH) to Post Q4 Earnings: What's in the Cards?

by Zacks Equity Research

UnitedHealth's (UNH) Q4 earnings are likely to have benefited from its operating segments and membership growth.

Zacks Equity Research

Will Humana (HUM) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Humana (HUM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Sreyoshi Mukherjee headshot

Bright Near-Term Outlook for Medical Info Systems Industry

by Sreyoshi Mukherjee

As the healthcare industry experiences rapid and unprecedented technological changes, let's take a look at a few promising medical info systems stocks.

Sapna Bagaria headshot

Why Should You Stay Away from Magellan Health (MGLN) Now?

by Sapna Bagaria

Pressure on revenues and earnings along with low profitability makes Magellan Health (MGLN) an unattractive stock now.

Zacks Equity Research

Magellan Health's Arm Expands Its Suite of Health Solutions

by Zacks Equity Research

Magellan Health's (MGLN) subsidiary Magellan Complete Care of Virginia adds to its range of services to help patients achieve better health outcomes.

Zacks Equity Research

Will UnitedHealth Exhibit Strong Share Price Gains in 2020?

by Zacks Equity Research

UnitedHealth (UNH) will continue to show operating efficiency in 2020 but its shares might be subject to volatility due to regulatory ambiguity through 2020 elections.

Sapna Bagaria headshot

Cigna Lags Industry in '19: Can Efforts Aid Recovery in 2020?

by Sapna Bagaria

Cigna's (CI) business streamlining and acquisitions are expected to drive growth in 2020.

Zacks Equity Research

Humana (HUM) Grows on Strong Medicare Business Expansion

by Zacks Equity Research

Humana (HUM) thrives well on the back of its well-performing Medicare business.

Zacks Equity Research

Humana (HUM) to Take Over Enclara for Enriched Healthcare

by Zacks Equity Research

Humana (HUM) to acquire hospice pharmacy Enclara Healthcare for boosting its capabilities.